

# PROVIDER Update



CONTRACTUAL | JUNE 10, 2022 | UPDATE 22-448sum | 3 PAGES

## Summary Update: Learn About the Medicare Prior Authorization Changes

### Drugs that require prior authorization now and other changes that start July 17, 2022

Wellcare By Health Net (Health Net\*) is making changes to the Medicare Advantage HMO/PPO prior authorization (PA) requirements. The PA changes apply to Direct Network physicians, hospitals, ancillary providers, and non-delegated fee-for-service participating physician groups.

To view the comprehensive provider update, which includes procedure codes for other services that require prior authorization on or after July 17, 2022, go to the Provider Library at [providerlibrary.healthnetcalifornia.com](http://providerlibrary.healthnetcalifornia.com). Select *Medicare Advantage > Updates and letters > 22-448 Learn About the Medicare Prior Authorization Changes*.

#### Part B Medications that require PA

New Centers for Medicare & Medicaid Services (CMS) medical benefit medication codes, effective **January 1, 2022**:

Code	Description
C9085	Injection, avalglucosidase alfa-ngpt, 4 mg
C9086	Injection, anifrolumab-fnia, 1 mg
C9088	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0172	Injection, aducanumab-avwa, 2 mg
J1952	Leuprolide injectable, camcevi, 1 mg
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
J9021	Injection, asparaginase, recombinant (Rylaze™), 0.1 mg
J9061	Injection, amivantamab-vmjw, 2 mg
J9272	Injection, dostarlimab-gxly, 10 mg
Q2055	Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed chimeric antigen receptor- (CAR-) positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

#### THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Supports (CS) Providers
- Enhanced Care Management (ECM) Providers

#### LINES OF BUSINESS:

- IFP (Ambetter from Health Net)
  - HMO/HSP
  - EPO
  - PPO
- Employer Group
  - HMO/POS/HSP
  - EPO
  - PPO
- Medicare Advantage (HMO/PPO) (Wellcare By Health Net)
- Cal MediConnect (Los Angeles/San Diego)
- Medi-Cal
  - Kern
  - Los Angeles
    - Molina
  - Riverside
  - Sacramento
  - San Bernardino
  - San Diego
  - San Joaquin
  - Stanislaus
  - Tulare

#### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)  
800-929-9224

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com)

#### PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)

\*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com) indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

New CMS medical benefit medication codes, effective **April 1, 2022**:

<b>Code</b>	<b>Description</b>
C9090	Injection, plasminogen, human-tvmh, 1 mg
C9091	Injection, sirolimus protein bound particles, 1 mg
C9092	Injection, triamcinolone acetonide suprachoroidal (Xipere®), 1 mg
C9093	Injection, ranibizumab, via sustained release intravitreal implant (Susvimo™), 0.1 mg
J0219	Injection, avalglucosidase alpha-ngpt, 4 mg
J0491	Injection, anifrolumab-fnia 1 mg
J0879	Injection, difelikefalin, 0.1 microgram
J9071	Injection, cyclophosphamide (Auromedics), 5 mg
J9273	Injection, tisotumab vedotin-tftv, 1 mg
J9359	Injection, loncastuximab tesirine-lypl, 0.075 mg
Q5124	Injection, ranibizumab-nuna biosimilar (Byooviz™), 0.1 mg
Q0221	Injection, tixagevimab and cilgavimab for certain adults and pediatric individuals, 600 mg

### **Medicare Advantage HMO/PPO PA changes**

Below are medical benefits plan PA requirement changes for direct network providers.

#### **Additions, effective July 17, 2022**

<b>Requirement</b>	<b>Comments</b>
Anesthesia	For spine manipulation or closed procedure
Cardiac	<ul style="list-style-type: none"> <li>• Cardiac monitor insertion</li> <li>• Endovenous ablation</li> <li>• Endovascular revascularization</li> <li>• Intracardiac catheter ablation</li> <li>• Vascular embolization and occlusion</li> <li>• Unlisted vascular surgery</li> </ul>
Dermatology	<ul style="list-style-type: none"> <li>• Benign lesion excision</li> <li>• Skin tag removal</li> </ul>
Diagnostic radiology	<ul style="list-style-type: none"> <li>• Bone marrow imaging</li> <li>• Liver/spleen &amp; gallbladder imaging</li> <li>• Radiopharmaceutical localization of tumor</li> <li>• Thyroid/parathyroid imaging</li> <li>• Unlisted procedure</li> </ul>
Ear, nose and throat (ENT)	<ul style="list-style-type: none"> <li>• Nasal/sinus endoscopy</li> <li>• Osseointegrated implant</li> <li>• Sinus procedures</li> <li>• Unlisted ENT procedure</li> </ul>
Flap procedures	

**Additions, effective July 17, 2022, continued**

<b>Requirement</b>	<b>Comments</b>
Gastroenterology	<ul style="list-style-type: none"> <li>• Cholecystectomy</li> <li>• Exploratory laparotomy</li> <li>• Laparoscopy procedures</li> <li>• Unlisted procedures</li> </ul>
Hernia repair	
Laboratory	<ul style="list-style-type: none"> <li>• Bone marrow culture</li> <li>• Chronic HCV assay</li> <li>• Engraftment analysis</li> <li>• Genetic analysis procedures</li> </ul>
Neurology	<ul style="list-style-type: none"> <li>• Electroencephalogram (EEG) or Video EEG (VEEG)</li> <li>• Neuroplasty procedures</li> <li>• Neurostimulators procedures</li> <li>• Sinusoidal vertical axis rotational testing</li> </ul>
Ophthalmology	<ul style="list-style-type: none"> <li>• Cataract procedures</li> <li>• Corneal procedures/transplant</li> <li>• Glaucoma procedures/surgery</li> <li>• Repair procedures of eye</li> <li>• Unlisted ophthalmological service/procedure</li> </ul>
Orthopedic	<ul style="list-style-type: none"> <li>• Endoscopy (foot, wrist)</li> <li>• Procedures of the foot or toes</li> <li>• Procedures of lower extremities</li> <li>• Procedures of upper extremities</li> <li>• Unlisted procedures</li> </ul>
Pulmonology	<ul style="list-style-type: none"> <li>• Unlisted pulmonary service</li> </ul>
Skin substitutes and biologicals	
Unlisted procedures	
Urology	<ul style="list-style-type: none"> <li>• Laparoscopy surgery (prostate)</li> <li>• Penile prosthesis</li> <li>• Prostate procedure</li> </ul>

**Use the online prior authorization tool**

It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization. To check if a CPT or HCPCS code requires authorization, go to the Online Prior Authorization Tool at <https://wellcare.healthnetcalifornia.com/for-providers/medicare-pre-auth.html>.

**Additional information**

If you have questions regarding the information contained in this update, contact the applicable Provider Services Center within 60 days as listed in the right-hand column on page 1.